Page last updated: 2024-09-05
deferasirox and Cytokine Release Syndrome
deferasirox has been researched along with Cytokine Release Syndrome in 1 studies
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Birlutiu, RM; Birlutiu, V; Chicea, L | 1 |
Other Studies
1 other study(ies) available for deferasirox and Cytokine Release Syndrome
Article | Year |
---|---|
Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Comorbidity; COVID-19 Drug Treatment; Cytokine Release Syndrome; Deferasirox; Drug Therapy, Combination; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Off-Label Use; Pneumonia, Viral; Respiration, Artificial; Retrospective Studies; Romania; SARS-CoV-2 | 2021 |